PIM-1 has demonstrated higher expression levels in various solid cancers, including prostate, colon, hepatic, pancreatic, and breast cancers, as well as hematological cancers like leukemia, multiple myeloma, and diffuse large B cell lymphomas (DLBCL) [10–16]. Here, PIM1 is linked to breast carcinoma.